Cargando…

Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry

BACKGROUND: We aimed to describe physician practice patterns in holding or continuing IBD therapy in the setting of COVID-19 infection, using the Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease [SECURE-IBD] registry. METHODS: IBD medications that were...

Descripción completa

Detalles Bibliográficos
Autores principales: Agrawal, Manasi, Brenner, Erica J, Zhang, Xian, Colombel, Jean-Frederic, Kappelman, Michael D, Ungaro, Ryan C, Gearry, Richard B, Kalpan, Gilaad G, Kissous-Hunt, Michele, Lewis, James D, Ng, Siew C, Rahier, Jean-Francois, Reinisch, Walter, Ruemmele, Frank M, Steinwurz, Flavio, Underwood, Fox E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717203/
https://www.ncbi.nlm.nih.gov/pubmed/33232456
http://dx.doi.org/10.1093/ecco-jcc/jjaa243
_version_ 1783619296648232960
author Agrawal, Manasi
Brenner, Erica J
Zhang, Xian
Colombel, Jean-Frederic
Kappelman, Michael D
Ungaro, Ryan C
Gearry, Richard B
Kalpan, Gilaad G
Kissous-Hunt, Michele
Lewis, James D
Ng, Siew C
Rahier, Jean-Francois
Reinisch, Walter
Ruemmele, Frank M
Steinwurz, Flavio
Underwood, Fox E
author_facet Agrawal, Manasi
Brenner, Erica J
Zhang, Xian
Colombel, Jean-Frederic
Kappelman, Michael D
Ungaro, Ryan C
Gearry, Richard B
Kalpan, Gilaad G
Kissous-Hunt, Michele
Lewis, James D
Ng, Siew C
Rahier, Jean-Francois
Reinisch, Walter
Ruemmele, Frank M
Steinwurz, Flavio
Underwood, Fox E
author_sort Agrawal, Manasi
collection PubMed
description BACKGROUND: We aimed to describe physician practice patterns in holding or continuing IBD therapy in the setting of COVID-19 infection, using the Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease [SECURE-IBD] registry. METHODS: IBD medications that were stopped due to COVID-19 were recorded in the SECURE-IBD registry in addition to demographic and clinical data. We conducted descriptive analyses to understand characteristics associated with stopping IBD medications in response to active COVID-19 infection. RESULTS: Of 1499 patients, IBD medications were stopped in 518 [34.6%] patients. On bivariate and multivariable analyses, a diagnosis of ulcerative colitis or IBD-unspecified was associated with a lower odds of stopping medication compared with Crohn’s disease (adjusted odds ratio [aOR] 0.6, 95% confidence interval [CI] 0.48, 0.75). When evaluating specific medications, 5-aminosalicylic acid was more likely to be continued [p <0.001] whereas anti-tumour necrosis factor therapy and immunomodulator therapy were more likely to be stopped [global p <0.001]. Other demographic and clinical characteristics did not affect prescription patterns. CONCLUSIONS: IBD medications other than immunomodulators were continued in the majority of IBD patients with COVID-19, in the international SECURE-IBD registry. Future studies are needed to understand the impact of stopping or continuing IBD medications on IBD- and COVID-19 related outcomes.
format Online
Article
Text
id pubmed-7717203
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77172032020-12-09 Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry Agrawal, Manasi Brenner, Erica J Zhang, Xian Colombel, Jean-Frederic Kappelman, Michael D Ungaro, Ryan C Gearry, Richard B Kalpan, Gilaad G Kissous-Hunt, Michele Lewis, James D Ng, Siew C Rahier, Jean-Francois Reinisch, Walter Ruemmele, Frank M Steinwurz, Flavio Underwood, Fox E J Crohns Colitis Short Reports BACKGROUND: We aimed to describe physician practice patterns in holding or continuing IBD therapy in the setting of COVID-19 infection, using the Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease [SECURE-IBD] registry. METHODS: IBD medications that were stopped due to COVID-19 were recorded in the SECURE-IBD registry in addition to demographic and clinical data. We conducted descriptive analyses to understand characteristics associated with stopping IBD medications in response to active COVID-19 infection. RESULTS: Of 1499 patients, IBD medications were stopped in 518 [34.6%] patients. On bivariate and multivariable analyses, a diagnosis of ulcerative colitis or IBD-unspecified was associated with a lower odds of stopping medication compared with Crohn’s disease (adjusted odds ratio [aOR] 0.6, 95% confidence interval [CI] 0.48, 0.75). When evaluating specific medications, 5-aminosalicylic acid was more likely to be continued [p <0.001] whereas anti-tumour necrosis factor therapy and immunomodulator therapy were more likely to be stopped [global p <0.001]. Other demographic and clinical characteristics did not affect prescription patterns. CONCLUSIONS: IBD medications other than immunomodulators were continued in the majority of IBD patients with COVID-19, in the international SECURE-IBD registry. Future studies are needed to understand the impact of stopping or continuing IBD medications on IBD- and COVID-19 related outcomes. Oxford University Press 2020-11-24 /pmc/articles/PMC7717203/ /pubmed/33232456 http://dx.doi.org/10.1093/ecco-jcc/jjaa243 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_modelThis article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
spellingShingle Short Reports
Agrawal, Manasi
Brenner, Erica J
Zhang, Xian
Colombel, Jean-Frederic
Kappelman, Michael D
Ungaro, Ryan C
Gearry, Richard B
Kalpan, Gilaad G
Kissous-Hunt, Michele
Lewis, James D
Ng, Siew C
Rahier, Jean-Francois
Reinisch, Walter
Ruemmele, Frank M
Steinwurz, Flavio
Underwood, Fox E
Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry
title Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry
title_full Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry
title_fullStr Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry
title_full_unstemmed Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry
title_short Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry
title_sort physician practice patterns in holding inflammatory bowel disease medications due to covid-19, in the secure-ibd registry
topic Short Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717203/
https://www.ncbi.nlm.nih.gov/pubmed/33232456
http://dx.doi.org/10.1093/ecco-jcc/jjaa243
work_keys_str_mv AT agrawalmanasi physicianpracticepatternsinholdinginflammatoryboweldiseasemedicationsduetocovid19inthesecureibdregistry
AT brennerericaj physicianpracticepatternsinholdinginflammatoryboweldiseasemedicationsduetocovid19inthesecureibdregistry
AT zhangxian physicianpracticepatternsinholdinginflammatoryboweldiseasemedicationsduetocovid19inthesecureibdregistry
AT colombeljeanfrederic physicianpracticepatternsinholdinginflammatoryboweldiseasemedicationsduetocovid19inthesecureibdregistry
AT kappelmanmichaeld physicianpracticepatternsinholdinginflammatoryboweldiseasemedicationsduetocovid19inthesecureibdregistry
AT ungaroryanc physicianpracticepatternsinholdinginflammatoryboweldiseasemedicationsduetocovid19inthesecureibdregistry
AT physicianpracticepatternsinholdinginflammatoryboweldiseasemedicationsduetocovid19inthesecureibdregistry
AT gearryrichardb physicianpracticepatternsinholdinginflammatoryboweldiseasemedicationsduetocovid19inthesecureibdregistry
AT kalpangilaadg physicianpracticepatternsinholdinginflammatoryboweldiseasemedicationsduetocovid19inthesecureibdregistry
AT kissoushuntmichele physicianpracticepatternsinholdinginflammatoryboweldiseasemedicationsduetocovid19inthesecureibdregistry
AT lewisjamesd physicianpracticepatternsinholdinginflammatoryboweldiseasemedicationsduetocovid19inthesecureibdregistry
AT ngsiewc physicianpracticepatternsinholdinginflammatoryboweldiseasemedicationsduetocovid19inthesecureibdregistry
AT rahierjeanfrancois physicianpracticepatternsinholdinginflammatoryboweldiseasemedicationsduetocovid19inthesecureibdregistry
AT reinischwalter physicianpracticepatternsinholdinginflammatoryboweldiseasemedicationsduetocovid19inthesecureibdregistry
AT ruemmelefrankm physicianpracticepatternsinholdinginflammatoryboweldiseasemedicationsduetocovid19inthesecureibdregistry
AT steinwurzflavio physicianpracticepatternsinholdinginflammatoryboweldiseasemedicationsduetocovid19inthesecureibdregistry
AT underwoodfoxe physicianpracticepatternsinholdinginflammatoryboweldiseasemedicationsduetocovid19inthesecureibdregistry